A Feasibility and Efficacy Study of Rapamycin and Erlotinib for Recurrent Pediatric Low-Grade Glioma (LGG)
A Feasibility and Efficacy Study of Rapamycin and Erlotinib for Recurrent Pediatric Low-Grade Glioma (LGG)
复制标题
DOI：
10.1002/pbc.24142
复制
发表时间：
2013-01-01
影响因子：
3.2
通讯作者：
Packer, Roger J.
中科院分区：
文献类型：
--
作者：
Yalon, Michal;Rood, Brian;Packer, Roger J.
背景确定雷帕霉素和厄洛替尼治疗复发性儿童低级别胶质瘤（LGGs）的毒性和疗效。方法.患者1年疾病控制。结论.雷帕霉素和厄洛替尼的组合在LGG儿童中耐受性良好。客观的反应是罕见的，虽然有长期的疾病稳定的一些患者与LGG，特别是在两个儿童与NF 1。儿科血液癌症2013; 60：71-76. (C)2012 Wiley Periodicals，Inc.
Background. To determine the toxicity and efficacy of rapamycin and erlotinib for the treatment of recurrent pediatric low-grade gliomas (LGGs). Methods. Patients 1 year disease control. Conclusions. The combination of rapamycin and erlotinib is well tolerated in children with LGGs. Objective responses were infrequent, although there was prolonged disease stabilization in some patients with LGGs, especially in two children with NF1. Pediatr Blood Cancer 2013; 60: 71-76. (C) 2012 Wiley Periodicals, Inc.